Assessing the implications for the pharma industry of the America Rescue Plan Act of 2021, which provides nearly two trillion dollars in funding for various government programs, including many related to public health.
Paul Rubin, Jacob W. Stahl, and Melissa Runsten
Advertisement
Paul Rubin is partner at Debevoise & Plimpton and co-chair of the firm’s Healthcare & Life Sciences Group. Jacob W. Stahl is counsel in Debevoise & Plimpton’s New York office and a member of the firm’s Litigation Department. Melissa Runsten is a corporate associate at the firm and a member of the Healthcare & Life Sciences Group.
Articles by Paul Rubin, Jacob W. Stahl, and Melissa Runsten
Advertisement
Latest Updated Articles
- The American Rescue Plan Act of 2021: Pharmaceutical Industry Impact
Published: March 23rd 2021 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
4
Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda
5
